Clinical trial · Observational
Pancreatic Cancer & Surgical Resection
AHPBA Registry Database (Collection of Clinical Data Related to Pancreatic Cancer & Treatment - Irreversible Electroporation (IRE))
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention. Secondary Objective(s) To collect data on adverse events and complications related to IRE treatment. The AHPBA (Americas Hepato-Pancreato-Biliary Association) will be responsible for data collection and will periodically audit the data for quality assurance purposes. The AHPBA will review outcomes reported by each participating Research Institution and if outcomes are in the lower percentile, the investigators will be offered support to analyze the reasons for the suboptimal outcomes and may seek support to improve outcomes. The participating Research Institutions will receive a certificate annually that acknowledges their participation in the Research Project.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NanoKnife procedure | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (9)
- measure
- Clinical data collected prospectively and post-operatively at different timepoints
- timeFrame
- pre-operatively and several timepoints post-operatively until 4 years
- description
- The primary objective of the study is to collect clinical data related to treatment outcomes of Pancreatic Irreversible Electroporation in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention.
- measure
- CBC blood test
- timeFrame
- pre-operatively and several timepoints post-operatively until 4 years
- description
- Check participants blood counts
- measure
- Chemistry blood test
- timeFrame
- up to 4 years following operation
- description
- Check the elements and minerals in the blood
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. more than 18 years of age 2. Diagnosed with pancreatic cancer and has consented to undergo the NanoKnife procedure per the treating physician 3. Willing and able to comply with the protocol requirements 4. Able to comprehend and sign the Informed Consent Form in English or Spanish Exclusion Criteria: * Patients who meet any of the following criteria will be excluded from the study: 1. Do not meet the Study Inclusion Criteria laid out above
References
Publications (0)
Data not yet available